Post-earnings recap
Reported
Thu, Jan 29, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing EPS expectations, Haemonetics Corp's stock rose by 6.81%, likely driven by positive sentiment around their long-term growth strategies. Investors may be encouraged by management's focus on innovation and product development, which could bode well for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.46 | N/A | -9.80% |
Overall, management expressed a cautious optimism about future growth. They emphasized their commitment to enhancing product offerings.
Management noted that they are focusing on long-term growth strategies.
They highlighted ongoing investments in product innovation.